These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 16038646)

  • 1. Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence.
    Lyman GH
    J Natl Compr Canc Netw; 2005 Jul; 3(4):557-71. PubMed ID: 16038646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colony-stimulating factors for the management of neutropenia in cancer patients.
    Dale DC
    Drugs; 2002; 62 Suppl 1():1-15. PubMed ID: 12479591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
    Aapro MS; Bohlius J; Cameron DA; Dal Lago L; Donnelly JP; Kearney N; Lyman GH; Pettengell R; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
    Eur J Cancer; 2011 Jan; 47(1):8-32. PubMed ID: 21095116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.
    Renner P; Milazzo S; Liu JP; Zwahlen M; Birkmann J; Horneber M
    Cochrane Database Syst Rev; 2012 Oct; 10():CD007913. PubMed ID: 23076939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.
    Aapro MS; Cameron DA; Pettengell R; Bohlius J; Crawford J; Ellis M; Kearney N; Lyman GH; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
    Eur J Cancer; 2006 Oct; 42(15):2433-53. PubMed ID: 16750358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines.
    J Clin Oncol; 1994 Nov; 12(11):2471-508. PubMed ID: 7964965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
    Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
    Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shifting guidelines for myeloid growth factors: applications in cancer chemotherapy.
    Daniel DB; Crawford J;
    Curr Hematol Rep; 2005 Nov; 4(6):441-5. PubMed ID: 16232380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-Cycle CSF use in breast cancer and NHL: guidelines and recommendations.
    Al-Kali A; Ozer H
    Oncology (Williston Park); 2006 Dec; 20(14 Suppl 9):7-12. PubMed ID: 17370923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myeloid growth factors clinical practice guidelines in oncology.
    Crawford J; Althaus B; Armitage J; Blayney DW; Cataland S; Dale DC; Demetri GD; Foran J; Heaney ML; Htoy S; Kloth DD; Lyman GH; Michaud L; Motl S; Vadhan-Raj S; Wong MK;
    J Natl Compr Canc Netw; 2005 Jul; 3(4):540-55. PubMed ID: 16038645
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States.
    Lyman G; Lalla A; Barron R; Dubois RW
    Curr Med Res Opin; 2009 Feb; 25(2):401-11. PubMed ID: 19192985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Balancing the benefits and costs of colony-stimulating factors: a current perspective.
    Lyman GH
    Semin Oncol; 2003 Aug; 30(4 Suppl 13):10-7. PubMed ID: 14508715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
    Rusthoven J; Bramwell V; Stephenson B
    Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacoeconomics of granulocyte colony-stimulating factor: a critical review.
    Barnes G; Pathak A; Schwartzberg L
    Adv Ther; 2014 Jul; 31(7):683-95. PubMed ID: 24989316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.
    Mitchell S; Li X; Woods M; Garcia J; Hebard-Massey K; Barron R; Samuel M
    J Oncol Pharm Pract; 2016 Oct; 22(5):702-16. PubMed ID: 26769697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A predictive model for neutropenia associated with cancer chemotherapy.
    Lyman GH
    Pharmacotherapy; 2000 Jul; 20(7 Pt 2):104S-111S. PubMed ID: 10905685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [G-CSF in oncology].
    Viret F; Gonçalves A; Tarpin C; Chabannon C; Viens P
    Bull Cancer; 2006 May; 93(5):463-71. PubMed ID: 16777624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk assessment and guidelines for first-cycle colony-stimulating factor use in the management of chemotherapy-induced neutropenia.
    Crawford J
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 4):22-8. PubMed ID: 16736985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence-based use of colony-stimulating factors in elderly cancer patients.
    Lyman GH; Kuderer N; Agboola O; Balducci L
    Cancer Control; 2003; 10(6):487-99. PubMed ID: 14652525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy.
    Cosler LE; Calhoun EA; Agboola O; Lyman GH
    Pharmacotherapy; 2004 Apr; 24(4):488-94. PubMed ID: 15098803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.